Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Pilot, Prospective, Open Label, Multicenter CT, to Evaluate the Safety and Efficacy of Palbociclib (PD0332991), a Cyclin-dependent Kinase 4 and 6 (CDK4 and CDK6) Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved

NCT02530320 is registered in ClinicalTrials.gov with Grupo Español de Investigación en Neurooncología as lead sponsor.

NCT NCT02530320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02530320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Pilot, Prospective, Open Label, Multicenter CT, to Evaluate the Safety and Efficacy of Palbociclib (PD0332991), a Cyclin-dependent Kinase 4 and 6 (CDK4 and CDK6) Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
Lead sponsor
Grupo Español de Investigación en Neurooncología
Phase
Phase 2
Overall status
Completed
Start date
October 25, 2015
Completion date
March 31, 2020
Enrollment
34 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

oligoastrocytoma, oligodendroglioma